FDA sagt "Nein"

https://endpts.com/...da-shows-another-testosterone-therapy-the-door/

LPCN 1144

http://ir.lipocine.com/2019-01-17-Lipocines-NASH-Therapy-Candidate-Achieves-Meaningful-Liver-Fat-Reduction-Based-on-Interim-Results

Allerdings gibt es Kritik am Studiendesign:

"I could conduct another webinar on clinical trial red flags based solely on todays LPCN liver fat study press release. Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs, etc etc. "

https://twitter.com/adamfeuerstein/status/1085877664991178753

LPCN 1144

wieder Kritik von AF:

"Not that anyone trading cares, but today’s LPCN iver fat (NASH? NAFLD? Something else?) data are worse than the data previously disclosed in January. Also, wow, so many changes to endpoint definitions. Carry on…."

https://twitter.com/adamfeuerstein/status/1105446714276761600

FDA verweigert TLANDO zum dritten Mal die Zulassung

https://endpts.com/...ir-oral-testosterone-drug-snubbed-again-by-fda/

Glückwunsch 

6 Mio. $ Offering

• 12 Mio. neue Aktien zu je 0,50$ ~ 6 Mio. $
  

Was für schlechtes Timing vom Management. Finger weg!

https://ir.lipocine.com/...blic-Offering-Of-Common-Stock-And-Warrants

• neues 52 WT
  
• MK 12 Mio. $